Pembrolizumab as Neoadjuvant Therapy for Resectable Stage IA3 to IIA Non-Small Cell Lung Cancer (NSCLC)

Stopped Study was terminated due to low recruitment.

Conditions

• Lung Cancer, Nonsmall Cell

Interventions

• DRUG: Pembrolizumab
• DRUG: Carboplatin
• DRUG: Paclitaxel
• DRUG: Pemetrexed

Sponsor

McGill University Health Centre/Research Institute of the McGill University Health Centre